Latest news with #BurjeelHoldingsPLC
Web Release
05-06-2025
- Business
- Web Release
Burjeel Holdings to Operate and Manage ADNOC's New State-of-the-art Das Hospital
Burjeel Holdings PLC, a leading super-specialty healthcare provider in the MENA region, listed on the Abu Dhabi Securities Exchange, has signed a contract to operate and manage ADNOC's Das Hospital at Das Island. This agreement supports ADNOC's commitment to strengthening emergency preparedness, improving healthcare accessibility, and promoting community wellbeing at Das Island. The new Das Hospital is designed to serve as the primary healthcare and emergency response hub for Das Island residents. With its advanced infrastructure and comprehensive range of services, the facility will provide round-the-clock care for ADNOC's workforce, residents, and emergency medical cases arising from nearby locations. Dr. Ghuwaya Al Neyadi, SVP, Group Medical & Wellbeing, ADNOC, said: 'Through this partnership with Burjeel Holdings, ADNOC's state-of-the-art Das Hospital will provide access to top-tier healthcare and emergency services for our employees, reinforcing our Energy for Wellbeing strategy. Our people are our most important asset and ADNOC will continue to prioritize their wellbeing and foster a healthy working environment.' Burjeel Holdings will oversee all clinical and administrative functions of the hospital. The facility includes a broad range of outpatient specialties—such as general surgery, internal medicine, family medicine, occupational health, ENT, dental, ophthalmology, and cardiac and pulmonary unit. It also houses a fully equipped emergency department with a minor operating room, licensed pharmacies, and a dedicated blood bank. John Sunil, Group CEO of Burjeel Holdings, said: 'We are proud to strengthen our partnership with ADNOC through the management of the new Das Hospital. This initiative reflects our continued commitment to extending advanced, high-quality healthcare to strategic and remote locations. Burjeel Holdings remains dedicated to clinical excellence, innovation, and agile operations in support of ADNOC's vision for a safer and healthier future.' Inpatient care is supported by 23 beds across male and female quarantine and critical care units, with the capability to manage both acute and chronic cases. The facility is further supported by advanced diagnostic imaging including X-ray, CT scan, and ultrasound, along with a dedicated physiotherapy and rehabilitation unit. Purpose-built for resilience and emergency responsiveness, the hospital includes a decontamination unit, ambulance bays, and a helipad to support medical evacuations from Das Island. Tele-consultation and tele-counselling services, vaccination programs, and health education initiatives will further enhance access and continuity of care. The Das Hospital builds upon the foundation of the former Das Medical Center, significantly enhancing healthcare provision on the island. With the integration of inpatient facilities, advanced diagnostic capabilities, and surgical services, the new hospital ushers in a new era of comprehensive, high-quality care for the Das community. It will also serve as the first responder for medical emergencies while supporting preventive and rehabilitative care aligned with ADNOC's occupational health guidelines. The new contract builds on Burjeel Holdings' long-standing partnership with ADNOC, which includes the successful operation and management of Al Dhannah Hospital, one of the largest healthcare facilities in the Al Dhafra region. The hospital will operate as part of an integrated care network, supported by the Group's advanced facilities, including its flagship unit, Burjeel Medical City. Burjeel Holdings' network is equipped with state-of-the-art medical technologies and specialized expertise to manage complex cases across a broad spectrum, including trauma, organ transplantation, women's health, pediatrics, orthopedics, spine surgery, and neurosciences, ensuring continuity of care from remote to tertiary-level settings.
Yahoo
03-06-2025
- Health
- Yahoo
New Space-Based Research May Pave the Way for First Astronaut with Diabetes
ISS National Lab-sponsored study launching on Axiom Mission 4 to advance diabetes management in space KENNEDY SPACE CENTER, Fla., June 3, 2025 /PRNewswire/ -- An investigation launching to the International Space Station (ISS) on Axiom Mission 4 (Ax-4) aims to advance diabetes management in microgravity and open access to space for more people. Researchers will demonstrate the accuracy of glucose monitoring and the viability of insulin on the ISS, with the long-term goal of supporting astronauts with insulin-dependent diabetes on future space missions. The ISS National Lab-sponsored project, Suite Ride, is a partnership between Axiom Space and Burjeel Holdings PLC, a healthcare services provider based in the United Arab Emirates. According to the International Diabetes Federation, one in nine adults worldwide—which amounts to nearly 590 million people—are living with diabetes. That number is expected to rise to more than 780 million people by 2045. "Individuals with insulin-dependent diabetes historically have been disqualified from flying to low Earth orbit," said Alex Rubin, medical operations group lead at Axiom Space. "A main objective of the study is to demonstrate that a condition such as this can be accurately monitored and treated in microgravity, with the intent of eventually flying a crew member with the condition." The team is sending several commercially available glucose monitors to the ISS to ensure they maintain a comparable level of accuracy in microgravity. One of the monitors samples interstitial fluid (the fluid filling the spaces between cells in the body) to measure glucose levels. Microgravity causes shifts in body fluids that could affect the accuracy of these devices. "We intend to demonstrate that the monitors can be relied upon, or if there is a difference due to microgravity, that it is something we can calibrate to and resolve," Rubin said. The study will also look at whether microgravity affects the integrity of insulin. Previous research showed that insulin pens can accurately administer doses during spaceflight. For this project, several different types of insulin will be sent to the ISS, with some stored at ambient or room temperature and some in cold stowage. The team will test the samples after they return to determine if microgravity had any effect. Results from this investigation could make it possible to support people with diabetes on future space missions, expanding the pool of those eligible to serve as crew members. Findings could also lead to improvements in diabetes monitoring and care in remote areas on Earth. "If we demonstrate that we can share data between a subject's glucose monitor in orbit and a physician on the ground in near real time, that could be implemented in a telemedicine setting with a clinician serving remote or austere locations on Earth," Rubin said. "If it can work in space, it could work on an oil rig, for example." We have come a long way in monitoring and treating diabetes, Rubin said. "There was a time where there was the perception that people with the disease couldn't do certain things. Today, you can play in the NFL, you can race cars, you can do all sorts of things that may have been difficult before. It only makes sense that the next barrier we break is human spaceflight." Ax-4 is scheduled to launch no earlier than June 10, 2025, at 8:22 a.m. EDT, from Florida. For additional information on ISS National Lab-sponsored investigations launching on Ax-4, visit our launch page. Download a high-resolution image for this release: Axiom Mission 4 Crew About the International Space Station (ISS) National Laboratory:The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space® (CASIS®) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website. As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page. Media Contact: Patrick O'Neill904-806-0035 PONeill@ International Space Station (ISS) National Laboratory Managed by the Center for the Advancement of Science in Space® (CASIS®) 1005 Viera Blvd., Suite 101, Rockledge, FL 32955 • 321.253.5101 • View original content to download multimedia: SOURCE International Space Station National Lab
